Zuberitamab, an innovative anti-CD20 monoclonal antibody, for patients with primary immune thrombocytopenia in China: a randomized, double-blind, placebo-controlled, phase 2 studyResearch in context

• Main Authors: Min Xu (Author), Jinhui Shu (Author), Shenxian Qian (Author), Jingming Guo (Author), Yuping Gong (Author), Ruibin Huang (Author), Shuye Wang (Author), Zeping Zhou (Author), Guolin Yuan (Author), Meijuan Huang (Author), Li-E Lin (Author), Shifeng Lou (Author), Yanping Song (Author), Qingchi Liu (Author), Hu Zhou (Author), Heng Mei (Author), Yu Hu (Author)
• Format: Book
• Published: Elsevier, 2024-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary: Background: Primary immune thrombocytopenia (ITP) is an autoimmune disease, and rituximab (RTX) induces long-term effect as second-line treatments. Zuberitamab is an innovative anti-CD20 monoclonal antibody, which was first developed in China and launched in diffuse large B lymphoma. This s...